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Seven polyene macrolides with alterations in the
polyol region and exocyclic carboxy group were
obtained via genetic engineering of the nystatin bio-
synthesis genes in Streptomyces noursei. In vitro
analyses of the compounds for antifungal and hemo-
lytic activities indicated that combinations of several
mutations caused additive improvements in their
activity-toxicity properties. The two best analogs
selected on the basis of in vitro data were tested for
acute toxicity and antifungal activity in a mouse
model. Both analogs were shown to be effective
against disseminated candidosis, while being con-
siderably less toxic than amphotericin B. To our
knowledge, this is the first report on polyene macro-
lides with improved in vivo pharmacological proper-
ties obtained by genetic engineering. These results
indicate that the engineered nystatin analogs can be
further developed into antifungal drugs for human
use.
INTRODUCTION
Systemic fungal infections represent a serious problem in medi-
cal care, as they usually affect patients whose immune systems
have been compromised as a result of HIV infection, anticancer
therapy, or immunosuppressive therapy after organ transplanta-
tion (Sims et al., 2005; Maschmeyer et al., 2007; Silveira and Hu-
sain, 2007). The number of antifungal agents that can be used to
treat such infections is currently limited to azoles (e.g., voricona-
zole), echinocandins (e.g., caspofungin), and polyenemacrolides
(e.g., amphotericin B). All the above-mentioned antifungals have
their own therapeutic limitations because of drug-drug interac-
tions, development of resistance, narrow spectrum of activity,
and toxicity (Scott and Simpson, 2007; Perlin, 2007; Spanakis
et al., 2006; Zotchev, 2003). The polyene macrolide amphoteri-
cin B (AmB) has been used for treatment of systemic fungal infec-1198 Chemistry & Biology 15, 1198–1206, November 24, 2008 ª200tions for several decades, showing excellent efficacy against
a number of fungal pathogens. At the same time, severe side
effects, such as nephrotoxicity, and suboptimal pharmacokinet-
ics, undermine therapeutic value of this antibiotic. A number of
AmB analogs, both semisynthetic and genetically engineered,
have been generated over the last 20 years in an attempt to re-
duce its toxicity and improve solubility (Falk et al., 1999; Paquet
and Carreira, 2006; Seco et al., 2005; Carmody et al., 2005). De-
spite that, no new AmB-based antifungal has appeared on the
market, except for the lipid and liposomal formulations. However,
studies of theAmBanalogshavegenerated important data on the
structure-activity relationship of polyene macrolides that may
also be at least partially applicable to other scaffolds belonging
to the same type of compounds. According to these studies,
the exocyclic carboxyl and the amino group of mycosamine
seem tobeparticularly important for selective toxicity andactivity
(Mazerski et al., 1995; Borowski, 2000). Moreover, Power et al.
(2008) have recently generated a mutant of Streptomyces nodo-
sus with inactivated ketoreductase (KR) domain in module 16 of
the AmB polyketide synthase (PKS) that was shown to produce
7-deoxy-7-oxy AmB. The latter compound has been shown to
retain antifungal activity, while having reduced hemolytic activity,
compared with that of AmB. To our knowledge, none of these
AmB analogs has been tested in vivo.
Polyene macrolides are mostly produced by Streptomyces
bacteria and exert their fungicidal action via interaction with
membrane sterols, resulting in the formation of highly organized
hydrophilic channels, through which small molecules and ions
can leak out (Omura and Tanaka, 1984; Teerlink et al., 1980;
Baginski et al., 2006). These antibiotics appear to have a higher
affinity toward membranes containing ergosterol (e.g., in fungi
and some parasites), compared with cholesterol-containing
membranes (mammalian cells) (Gagos et al., 2005). Still, polyene
macrolides bind to the cholesterol-containing membranes to
some extent, thus causing lysis of particularly vulnerable cells
(e.g., in kidneys) and subsequent organ damage.
The polyene macrolide antibiotic nystatin produced by Strep-
tomyces noursei ATCC 11455 is an important antifungal agent
used in human therapy for treatment of superficial mycoses. Its
use for treatment of systemic mycoses is precluded by toxicity,8 Elsevier Ltd All rights reserved
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Only reductive domains in the nystatin PKS modules are shown.solubility problems, and lower antifungal activity, compared with
that of AmB (Hamilton-Miller, 1973). The nystatin biosynthetic
pathway has been established after cloning of the entire biosyn-
thetic gene cluster (Brautaset et al., 2000). It comprises assembly
of the 38-member macrolactone ring, followed by oxidation of
a C-16 methyl group, attachment of deoxysugar mycosamine
at C-19, and hydroxylation at C-10 (Fjærvik and Zotchev, 2005)
(Figure 1).
Using genetic engineering, we have recently obtained a
heptaene nystatin analog S44HP with antifungal activity consid-
erably higher than that of nystatin and equal to that of AmB
(Bruheim et al., 2004). S44HP is structurally similar to AmB but
has significantly different properties. For example, S44HP was
found to be 10 times more soluble than AmB and, despite
having a lower maximal tolerated dose (MTD) value compared
with the latter, seems to have a wider therapeutic window
(MTD-LD50 dose interval) (Treshchalin et al., 2005). We hypothe-
sized that further derivatization of S44HP might yield new poly-
ene macrolides with improved pharmacological properties,
which can be useful for development of safer antifungals. In
the present work, we report the generation of new nystatin and
S44HP analogs by means of manipulation of the nystatin biosyn-
thetic genes and their biological characterization. Two of these
analogs tested in vivo displayed high efficacy and considerably
lower acute toxicity, compared with AmB, suggesting that they
can become lead compounds for development of new antifungal
drugs for human use.Chemistry & Biology 15, 1198–12RESULTS AND DISCUSSION
Specific Change in the C-9–C-10 Polyol Region
of Nystatin Leads to a Significant Reduction
of Hemolytic Activity
The polyol region on the polyene macrolide molecule has re-
cently become a potentially interesting target for modification
through biosynthetic engineering. Caffrey and co-workers have
demonstrated that replacement of the C-7 hydroxyl group on
the AmBmolecule with a keto group leads to over 10-fold reduc-
tion of in vitro hemolytic activity and4-fold reduction of antifun-
gal activity (Power et al., 2008). On the nystatin A1 molecule, the
C-1–C-15 polyol region is interrupted by a saturated C-9–C-10
bond formed as a result of the activity of KR, dehydratase
(DH), and enoyl reductase (ER) domains in the module 15 of
the nystatin PKS NysJ (Figure 1). To gain a better insight into
structure-activity relationship of nystatin, we inactivated DH15
domain of NysJ by site-specific mutagenesis of the active site
His followed by gene replacement in S. noursei NDA59, yielding
mutant NJDH15 (see Table S1 available online). The host strain
NDA59 has a nysA deletion, and nystatin production can be
restored to almost 100% by complementation with nysA gene
(Brautaset et al., 2003).
Mutant NJDH15 was complemented with the nysA gene, cul-
tivated in the fermentor, and DMSO extracts were assayed for
polyene production by liquid chromatography (LC)-diode array
detector (DAD)-time of flight (TOF). The analysis unraveled the06, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1199
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(A) Molecular structures of nystatin and its analogs generated by biosynthetic engineering.
(B) Molecular structures of amphotericin B analogs produced via manipulation of biosynthetic genes (Carmody et al., 2005; Power et al., 2008).production of an analog with a mass (m/z) corresponding to the
stoichiometric formula of nystatin (less than 2 ppm difference
from the theoretical mass) in both ESI+ (positive ionization) and
ESI (negative ionization) modes (Figure S1). The volumetric
production yield of this analog, denoted BSG002 (0.88 ±
0.04 g/l) was about 30%of the nystatin production level obtained
in the wild-type strain under the same conditions (Table S2).
Since the expected change shall affect the C-9–C-10 region,
we hypothesized that the NysL hydroxylase (Volokhan et al.,
2006) might not recognize the altered C-9–C-11 region on the
new molecule, thus failing to perform C-10 hydroxylation. Thus,
a new analog with a molecular weight identical to that of nystatin
can be explained if this compound has acquired a C-9 hydroxyl,
but lacks C-10 hydroxyl group. To verify this hypothesis, the1200 Chemistry & Biology 15, 1198–1206, November 24, 2008 ª200major compound produced by the NJDH15 mutant was purified
using preparative high-pressure liquid chromatography (HPLC),
and the concomitant nuclear magnetic resonance (NMR) analy-
sis (see Supplemental Text and Figure S2) clearly supported our
hypothesis that BSG002 indeed represents 9-hydroxy-10-deoxy
nystatin (Figure 2).
Purified BSG002 (purity >95% and concentration of active
principle adjusted according to the purity) was then subjected
to the in vitro tests for antifungal and hemolytic activities (see Ex-
perimental Procedures). BSG002 was found to be at least 2-fold
less hemolytic, compared with nystatin. However, its antifungal
activity was simultaneously reduced 4-fold (Table 1). Accord-
ing to the model of the channel formed by polyene macrolides,
the hydroxyl groups in the polyol region create a hydrophilic8 Elsevier Ltd All rights reserved
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One could expect that the addition of a hydroxyl group at C-9
might increase the conductance of the channel, and hence in-
crease antifungal activity, while removal of C-10 hydroxyl should
have no effect, as suggested by the data on 10-deoxy nystatin
(Volokhan et al., 2006).
Replacement of the C-16 Carboxyl on the Nystatin
Molecule with a Methyl Group Reduces Hemolytic
Activity Without Affecting the Antifungal Activity
Replacement of a C-16 carboxyl with amethyl group on the AmB
molecule by means of inactivation of the methyl oxidase AmphN
yielded a less hemolytic analog with retained antifungal activity
(Carmody et al., 2005). The S. noursei nystatin gene cluster con-
tains a nysN gene encoding a putative P450 monooxygenase
earlier implicated in oxidation of the C-16 methyl to afford a car-
boxyl group on the mature antibiotic molecule (Brautaset et al.,
2000). Accordingly,S. nourseimutantCL346AS, carrying amuta-
tion in the nysN gene replacing the conserved Cys residue
(Cys346) of NysN presumed to be responsible for heme binding
with Ala, was constructed (Table S1). This mutation was pre-
dicted to abolish activity of NysN on the basis of the data re-
ported for another P450 monooxygenase (Vatsis et al., 2002).
Mutant strain CL346AS was cultivated in the fermentor and ana-
lyzed for production of polyene macrolides, as described above.
The expected mass corresponding to the stoichiometric formula
of 16-decarboxy-16-methyl nystatin (C47H77NO15) was identified
(<3 ppm difference from the theoretical mass) in both ESI+ and
ESI modes in the culture extract (Figure S3). The production
level of 16-decarboxy-16-methyl nystatin (16-DecNys) was
very low (0.06 ± 0.01 g/l) and represented less than 2%, com-
pared with the nystatin production in the wild-type strain (Table
S2). Similarly low production yield of 16-decarboxy-16-methyl
AmB analog has been observed in S. nodosus upon inactivation
of the amphN gene (Carmody et al., 2005). Since we did not
observe any abnormal growth for the CL346AS mutant, it seems
unlikely that 16-DecNys is toxic to the producing organism. Po-
tentially, accumulation of the latter analog may cause feedback
Table 1. In Vitro Determined Antifungal and Hemolytic Activities
of the Genetically Engineered Nystatin Analogs
Compound MIC50 (mg/ml)
a MIC90 (mg/ml)
a HC50 (mg/ml)
b
Nystatin 1.2 ± 0.2 2.0 ± 0.3 85
BSG002 4.8 ± 0.4 10.5 ± 3.5 180
16-DecNys 1.3 ± 0.4 1.8 ± 0.5 175
AmB 0.12 ± 0.03 0.19 ± 0.03 2.6
S44HP 0.12 ± 0.03 0.20 ± 0.03 2.5
BSG005 0.07 ± 0.02 0.12 ± 0.03 4.0
BSG013 0.25 ± 0.07 0.43 ± 0.07 3.0
BSG017 0.47 ± 0.15 0.92 ± 0.03 3.3
BSG020 0.15 ± 0.03 0.19 ± 0.03 9.0
BSG031 0.18 ± 0.06 0.37 ± 0.07 3.8
The ± values represent maximum deviation from the mean.
a Tested as described in Nedal et al., (2007) usingCandida albicans ATCC
10231 as a test organism.
b Tested by using horse blood erythrocytes and antibiotic concentrations
ranging between 0 and 200 mg/ml.Chemistry & Biology 15, 1198–12inhibition of the nystatin biosynthetic pathway by an unknown
mechanism (see below).
In vitro hemolytic assay of the purified 16-DecNys (purity 75%
and concentration of active principle adjusted according to the
purity) revealed about 2-fold increased HC50 value for this com-
pound, compared with the parental antibiotic nystatin (Table 1).
At the same time, its antifungal activity remained unchanged, as
judged from the MIC50/MIC90 values forCandida albicans, which
were 1.2 ± 0.2/2.0 ± 0.3 mg/ml and 1.3 ± 0.4/1.8 ± 0.5 mg/ml for
nystatin and 16-DecNys, respectively (Table 1). Combined,
these data imply that replacement of the C-16 carboxyl with
a methyl group reduces the toxicity of nystatin, while having no
effect on its antifungal activity. These data are in good agree-
ment with the analogous result previously documented for
16-decarboxy-16-methyl AmB (Carmody et al., 2005). Because
of the low yield, we were unable to produce 16-DecNys in quan-
tity and purity sufficient for NMR analysis of the structure and
in vivo animal experiments.
C-16 Modification of the Heptaene Nystatin Analog
S44HP Yields Less Hemolytic and More Active
Polyene Macrolide
Encouraged by the in vitro data obtained for 16-DecNys (see
above), we introduced identical C-16 modification on the mole-
cule of the heptaene nystatin analog S44HP, which was shown
to have 6-fold higher in vitro antifungal activity than nystatin
(Bruheim et al., 2004). The CL346AS mutation in the nysN gene
was introduced into the S44HP-producing mutant S. noursei
GG5073SP (Borgos et al., 2006a), generating mutant BSM1
(Table S1). BSM1was cultivated in the fermentor and assayed for
polyene macrolides by LC-DAD-TOF. The expected mass corre-
sponding to the stoichiometric formula of 16-decarboxy-16-
methyl-28,29-didehydro nystatin (C47H75NO15), was identified
in the culture extract (<1.5 ppm difference from the theoretical
mass) in the ESI mode (Figure S4), and this compound was
designated BSG005 (Figure 2). Interestingly, the BSG005
production level by BSM1 in the fermentor (0.53 ± 0.01 g/l)
was about 40%, compared with the S44HP production level by
parental strain GG5073SP (Table S2). This was20 times higher
than the relative production level of 16-DecNys by the analogous
nysNmutant CL346AS constructed on thewild-type background
(see above), and the biological reason for this discrepancy is un-
known. It is possible that the C28-29 double bond in BSG005
somehow negatively affects its ability to inhibit the nystatin bio-
synthetic pathway, whereas 16-DecNys, which has a saturated
C28-C29 bond, has much higher potential for inhibiting the path-
way. Chemical structure of the expected BSG005 analog, 16-
decarboxy-16-methyl-28,29-didehydro nystatin, was confirmed
by NMR experiments on purified compound (Figures S5 and S6).
In vitro assay for the purified BSG005 (purity >95%) revealed
its 2-fold and 20-fold increased antifungal activity, compared
with S44HP and nystatin, respectively (Table 1; Figure S7). At the
same time, its hemolytic activity was reduced 1.5-fold, com-
pared with S44HP (Table 1). Together, these data imply that
replacement of the C16-carboxyl group on S44HP with a methyl
has a positive effect on the pharmacological properties of this
compound under the conditions tested. These results are in
agreement with the similar data reported for noncarboxylated
analogs of both AmB and rimocidin (Seco et al., 2005; Carmody06, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1201
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latter two compounds have not been reported.
C-5 and C-7 Keto Modifications in the S44HP Polyol
Region Yield Analogs with Reduced Antifungal
and Hemolytic Activities
According to the current model, the polyol regions of antibiotic
molecules with multiple hydroxyl groups outline the inner part
of the channel piercing the target cell membrane (Baginski
et al., 2002). The hydrophilic properties of the channel are most
likely affected by the number and position of the hydroxyls, and
thus variation of these properties might theoretically affect the
channel’s ion selectivity and conductivity. Power et al. (2008)
have reported biosynthetic engineering of the 7-oxo-AmBanalog
with reduced hemolytic activity. We decided to generate S44HP
analogs, where either C-5 or C-7 hydroxyls in the polyol region
were replaced with keto groups, and to compare their biological
properties. The KR17 domain of the nystatin PKS NysJ protein is
responsible for catalyzing the reduction the C-5 keto group to
afford the C-5 hydroxyl during the biosynthesis of the nystatin
macrolactone ring (Brautaset et al., 2000) (Figure 1). To generate
anS44HPanalogwith retainedC5-keto group,we introduced the
double mutation TA5145FE affecting the proposed KR17 active
site Tyr residue in the nystatin PKS NysJ. The KR16 domain of
the NysJ PKS is responsible for catalyzing the reduction the
C-7 keto group to afford the C-7 hydroxyl on the nystatin mole-
cule. To generate an S44HP analog with retained C7-keto group,
we introduced thedoublemutationYA3404FEaffecting theKR16
active site Tyr3404 residue in NysJ. The KR17 and KR16 muta-
tions were individually introduced to the S. noursei mutant
GG5073SP, generating mutants BSM2 and BSM4, respectively
(Table S1).
The two latter strains were cultivated in the fermentor and
assayed for polyene macrolides by LC-DAD-TOF. Accurate
masses, which correlatedwell with the expected 5-oxo-5-deoxy-
28,29-didehydro nystatin and 7-oxo-7-deoxy-28,29-didehydro
nystatin (both with stoichiometric formula C47H71NO17) were
found in ESI and ESI/ESI+ modes, respectively, (<5 ppm
difference from the theoretical mass, Figures S8 and S9). The
compounds produced by the BSM2 and BSM4 mutants were
designated BSG013 and BSG017, respectively (Figure 2). The
volumetric production yields of BSG013 (0.73 ± 0.01 g/l) and
BSG017 (0.63 ± 0.07 g/l) correspond to about 56% and 49%, re-
spectively, of the S44HP production yield obtained for the paren-
tal strain GG5073SP (Table S2). Chemical structure of BSG013
wasalsoconfirmedbyNMRexperiments (FigureS5). Structurally,
BSG013 and BSG017 seem to be identical to the previously
reported polyene macrolides mycoheptin (Borowski et al., 1978)
and candidin (Volpon and Lancelin, 2002), respectively.
Next, purified BSG013 and BSG017 (purity >95%) were tested
in vitro for hemolytic and antifungal activities, as described
above. Compared to S44HP, BSG013 showed 2-fold reduced
antifungal activity with concomitantly 1.2-fold increased HC50
value (Table 1; Figure S7). BSG017 showed a 4-fold reduced
antifungal activity and 1.3-fold increased HC50 value compared
to S44HP (Table 1; Figure S7). These data indicated that substi-
tutions of C-5 or C-7 hydroxyls with keto groups reduce both
antifungal and hemolytic activities of the S44HP analogs. These
data were consistent with those reported for 7-oxo AmB analog,1202 Chemistry & Biology 15, 1198–1206, November 24, 2008 ª200where reduction of both antifungal and hemolytic activities have
been observed (Power et al., 2008). However, reduction of hemo-
lytic activity upon replacement ofC-5andC-7hydroxylswith keto
groups on S44HP was not as dramatic as in the case of 7-oxo
AmB.
Combination of C-16 with C-5 or C-7 Keto Modifications
on S44HP Results in Analogs with Further Reduced
Hemolytic Activity and High Antifungal Activity
Considering that BSG005, BSG013, and BSG017 were all less
hemolytic than S44HP in vitro, we decided to combine the corre-
sponding modifications on these molecules in an attempt to
obtain an analog with further reduced toxicity. The CL346AS
nysN mutation that was used to construct mutant BSM1 was
introduced into the BSG013- and BSG017-producing mutants
BSM2 and BSM4, yielding recombinant strains BSM3 and
BSM5, respectively (Table S1). The two latter strains were culti-
vated in the fermentor, and production of polyene macrolides
was assessed by LC-DAD-TOF. Accurate masses which corre-
lated well with the 5-oxo-5-deoxy-16-decarboxy-16-methyl-
28,29-didehydro nystatin and 7-oxo-7-deoxy-16-decarboxy-
16-methyl-28,29-didehydro nystatin (both with stoichiometric
formula C47H73NO15), were found in ESI and ESI+ modes (all
with <3 ppm difference from the theoretical masses, Figures
S10 and S11). The analogs identified were designated BSG020
and BSG031, respectively (Figure 2). In addition, tandem mass
spectrometer (MS)-MS data were used to confirm the chemical
structure of BSG020 (Figure S12). The volumetric production
yields of BSG020 (0.26 ± 0.02 g/l) and BSG031 (0.37 ± 0.04 g/l)
corresponded to20% and 29%, respectively, of that of S44HP
produced by the parental strain GG5073SP (Table S2). These
data demonstrate that several alterations can simultaneously
be introduced into the nystatin biosynthetic pathway without
dramatically affecting production yields of new analogs.
The purified compounds BSG020 andBSG031 (93%and 80%
pure, respectively) were subjected to in vitro activity and toxicity
assays as described above. The data from these experiments
showed that BSG020 and BSG031 had 3.5- and 1.5-fold
increased HC50 values, comparedwith S44HP, respectively, and
that their antifungal activities were improved compared to those
of their parental oxo-analogs. (Table 1 and Figure S7). Together,
these data indicate that the combination of the oxo substitutions
in the polyol region and C-16 methyl group can potentially be
beneficial for improvement of therapeutic index of S44HP. It
should be noted that AmB analogs with combined C-15-oxo
and C-16-methyl modifications have been obtained by Power
et al. (2008). Unfortunately, yields of these analogs had appar-
ently been too low for purification of substantial amounts of
materials, although crude samples clearly exhibited antifungal
activity. We have failed to generate a mutant producing C-15-
oxo analog of S44HP in detectable amounts, although two
alternative mutations for KR12 inactivation in the nystatin PKS
NysI were attempted (data not shown).
BSG005 and BSG020 Have Considerably Reduced
Toxicity, and BSG005 also Displays Improved Antifungal
Activity, Compared with AmB In Vivo
On the basis of all the accumulated in vitro data (see above), one
nystatin analog (BSG002) and two S44HP analogs (BSG005 and8 Elsevier Ltd All rights reserved
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antifungal activity against disseminated candidosis in a mouse
model. First, BSG002 was investigated and compared to its
parental compound nystatin. Preparations containing different
antibiotic concentrations were administered intravenously, and
median lethal and maximum tolerated doses (LD50 and MTD
values, respectively) were calculated from the experimental
data. BSG002 was shown to have considerably lower acute tox-
icity than nystatin in these experiments; the MTD/LD50 values for
BSG002 and nystatin were 53.7/61.7 mg/kg and 7.1/8.5 mg/kg,
respectively (Table 2). These data were in good agreement with
the corresponding in vitro data (Table 1). BSG002 and nystatin
were then used in a mouse candidosis model in order to assess
their antifungal activity in vivo (see Experimental Procedures).
The fungal load in the kidneys of C. albicans infected animals
treated with antibiotics was determined and compared with
that of the untreated animals. In this experiment, nystatin
demonstrated in vivo antifungal activity (reduction of Candida
colony-forming units [CFU] in kidneys by a factor of >10) at doses
equal or higher than 4 mg/kg, whereas no activity was shown for
BSG002 at doses up to 32mg/kg (Table 2). The fact that BSG002
lacks activity in a mouse model of candidosis, while having
reduced but still significant activity in vitro, suggests that such
factors as stability in vivo and pharmacokinetics might play a
decisive role for therapeutic usefulness of polyene macrolides.
Next, BSG005andBSG020were tested in similar experiments,
and the data obtained for both analogs clearly demonstrated
higher MTD and LD50 values, compared with those for both
S44HP and AmB, suggesting that they have considerably lower
toxicity in vivo (Table 2). Compared with S44HP, the MTD value
was increased 13-fold for both BSG005 and BSG020, indicat-
ing significant reduction of toxicity. These data were in some
agreement with the in vitro data on hemolytic activities of these
compounds, whereas the effects in vivo were much more pro-
found (Table 1). When assessed for efficacy in a mouse candido-
sis model, the effective doses for AmB, S44HP, BSG005, and
BSG020 (Table 2) were considerably lower than that for nystatin
and correlated well with the in vitro data for antifungal activity
as presented in Table 1. BSG005 displayed in vivo antifungal
activity slightly higher than those of both AmB and S44HP,
whereas the antifungal activity of BSG020 was somewhat
Table 2. In Vivo Acute Toxicity and Antifungal Activity of
Engineered Nystatin Analogs Tested in a Mouse Model of
Disseminated Candidosis
Compound MTD mg/kg LD50 mg/kg
Candida kidney load,
CFU/g (% MTD)a,b
Control NA NA 6.5 3 104
Nystatin 7.1 8.5 3.4 3 103 (56%)
BSG002c 53.7 61.7 6.3 3 104
S44HP 0.6 2.1 4.2 3 103 (94%)
BSG005 7.8 15.4 2.9 3 103 (10%)
BSG020 7.9 10.5 6.5 3 103 (10%)
AmB 2.0 2.8 4.0 3 103 (40%)
aAfter 4 days of single dose administration of 0.8 mg/kg, except for
nystatin (4 mg/kg), BSG002 (32 mg/kg) and S44HP (0.6 mg/kg).
b Average data for 3 animals.
cNo activity demonstrated for doses up to 32 mg/kg.Chemistry & Biology 15, 1198–12reduced compared to these control compounds. Again, these
data were in agreement with the in vitro antifungal activity tests
showing that BSG020 displays a lower antifungal activity than
doesBSG005 (Table 1).Most importantly, these in vivo antifungal
activitieswere observed at doses corresponding to only10%of
MTD for both BSG005 and BSG020. At the same time, 40% and
94% MTD doses for AmB and S44HP, respectively, had to be
used to achieve the same efficacy in reducing fungal kidney
load. The latter data confirm that both BSG005 and BSG020
have favorable activity/toxicity properties, compared with AmB,
under these conditions and suggest that theymaybecomeprom-
ising lead compounds for further development as antifungal
agents.
Structure-Activity-Toxicity Relationship
of Engineered Nystatin Analogs
The impact of modifications introduced into three different
regions of the nystatin molecule on its antifungal activity and tox-
icity has been investigated both in vitro and in vivo in this study.
In particular, the polyene region (C-28–C-29), the exocyclic
carboxyl group (C-16), and the polyol region (C-5, C-7, C-9,
and C-10) were targeted for modifications. The data obtained
for S44HP supports our previous observation (Bruheim et al.,
2004) that modification of the polyene region resulting in the
appearance of seven instead of four conjugated double bonds
increases both antifungal activity and toxicity. This result is con-
sistent with significantly higher antifungal activity and toxicity
reported for the heptaene polyene macrolide AmB, compared
with that of nystatin. The data obtained for C-16 methyl
substituted S44HP analog demonstrated that this modification
leads to increased antifungal activity and reduced toxicity,
whereas the analogous modification reported for AmB caused
reduced toxicity while leaving antifungal activity presumably
unchanged (Carmody et al., 2005). Modifications in the polyol
region of nystatin (C-5, C-7, and C9+C10) yielded compounds
with both reduced antifungal activity and toxicity, whereas the
effect varied among these modifications. Interestingly, the C-7
modification in AmB (Power et al., 2008) had no effect on antifun-
gal activity, while causing reduced toxicity, thus further confirm-
ing differences between AmB and S44HP in terms of structure-
activity relationship. Taken together, our data suggest that the
polyol and polyene region, as well as C-16 exocyclic, are all
important for the antifungal activity and toxicity of nystatin and
S44HP. Moreover, our data obtained for the analogs combining
different modifications indicate that simultaneous introduction of
C-16 methyl and C-5 keto group on S44HPmay be beneficial for
the activity/toxicity profile. Although some of these results could
potentially have been expected on the basis of the data available
for the genetically engineered AmB analogs (Carmody et al.,
2005; Power et al., 2008), certain modifications in the polyol
region of nystatin, such as at C-7 and C-9/C-10, had a significant
negative effect on antifungal activity, while contributing little to
the reduction of toxicity.
SIGNIFICANCE
There is an urgent need for efficient and safe antifungal
agents because of the growing number of life-threatening
systemic fungal infections. Polyene macrolide antibiotics06, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1203
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Engineered Nystatin Analogsare potent fungicidal agents, but their medical usefulness is
hampered by considerable toxicity. A series of new analogs
of the polyene macrolide antibiotic nystatin was generated
by means of biosynthetic engineering. Testing of these ana-
logs in vitro for antifungal and hemolytic activities provided
important new data on structure-activity-toxicity relation-
ship and allowed selection of the most active and least toxic
analogs. In vivo experiments in amousemodel revealed that
two new nystatin analogs, BSG005 and BSG020, are at least
as efficient as AmB, the only polyene macrolide currently
used for treatment of systemic fungal infections, against
disseminated candidosis, while being considerably less
toxic. The two analogs might therefore represent promising
lead compounds for further development of antifungal drugs
for human therapy.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Media, and Growth Conditions
Plasmids, phages, and bacterial strains used in the present study are described
in Table S1. S. noursei and Escherichia coli strains were maintained and genet-
ically manipulated as described elsewhere (Sekurova et al., 1999; Sambrook
et al., 1989).CultivationsofS. noursei strains for productionof analogswereper-
formed in fed-batch fermentation essentially as described elsewhere (Borgos
et al., 2006a), except for the use of SAO-50 medium, which contained double
amounts of all nutrients, compared to SAO-40 (Borgos et al., 2006a). Analysis
of polyene macrolides produced was done as reported elsewhere (Bruheim
et al., 2004). The gene replacements were performed through conjugation of
thecorrespondingvectors (seebelow) into theS.noursei,verificationofchromo-
somal integration, and selection for double homologous recombination, as de-
scribed elsewhere (Sekurova et al., 1999). Gene replacements were performed
in nysA-deficient mutants NDA59 (Brautaset et al., 2003) and GG5073SP (Bor-
gos et al., 2006a), and the resulting recombinant strains were complemented
with the nysA gene to restore the polyene macrolide biosynthesis.
DNA Manipulation, Sequencing, and PCR
GeneralDNAmanipulationswereperformedasdescribedelsewhere (Sambrook
et al., 1989). DNA fragments from agarose gels were purified using QIAEX II kit
(QIAGEN, Germany). Southern blot analyses were performed with the digoxige-
nin-11-dUTPHigh Prime labeling kit (RocheMolecular Biochemicals) according
to themanufacturer’s instruction. Oligonucleotide primerswere purchased from
MWGBiotech (Germany). ThePCRswereperformedwith theGCRichPCRSys-
tem (Roche Molecular Biochemicals) on Eppendorf Mastercycler (Eppendorf,
Germany), using conditions described elsewhere (Brautaset et al., 2003). DNA
sequencing was performed at MWG Biotech (Germany).
Construction of Gene Replacement Vectors
Inactivation of NysJ DH15
The 3.33 kb BclI/SphI fragment of recombinant phage N20 (Table S1) was
ligated into the BamHI/SphI sites of pGEM-11zf+. From the resulting plasmid,
the 3.34 kb EcoRI/HindIII fragment was isolated and ligated into the corre-
sponding sites of plasmid pGEM-3zf+, yielding pDH15-B. The latter plasmid
was used as a template for site-directed mutagenesis to introduce the DH15
mutation H966F using the mutagenic oligonucleotides Mut-DH15-1: 50-CACC
CCTGGCTCGCCGACTTCGTCGTCGGCGGCATGGTC30 (sense) and Mut-
DH15-2: 50-GACCATGCCGCCGACGACGAAGTCGGCGAGCCAGGGGTG30
(antisense). Altered nucleotides are indicated in bold, and the introducedmuta-
tion eliminated the originally present BrtI recognition site (not shown). Mutation
was first confirmed by BrtI restriction digestion and then verified by DNA
sequencing. The plasmid-containing mutation was designated pDH15-mut.
The 1.6 kb EcoRI/SacI fragment of pDH15-B, the 1.1 kb HindIII/BglII fragment
of pDH15-B, and the mutated 0.64 kb SacI/BglII fragment from pDH15-mut
were isolated and ligated together with the 3.1 kb EcoRI/HindIII fragment of
pSOK201 (Zotchev et al., 2000) (Table S1), yielding DH15 inactivation vector
pSH15-123.1204 Chemistry & Biology 15, 1198–1206, November 24, 2008 ª200Inactivation of nysN
The4.1 kbNcoI/XbaI fragment from the recombinant phageN95 (Table S1)was
cloned into the corresponding sites of the plasmid pLITMUS28. From the re-
sulting construct, the entire 4.1 kb insert was excised with EcoRI/HindIII and
cloned into the corresponding sites of pGEM11-zf+. From the resulting plas-
mid, pGEM11nysN4.1, the 1.5 kb region including the nysN active site was
PCR-amplified with primers conA-1F: 50-TTTTGAATTCTTCAAGCCGATGAGC
C-30 and conA-1R: 50-TTTTAAGCTTGGTCGAAC AGGTCCGG-30, introducing
EcoRIandHindIII sites (underlined) into thePCRproduct. Thesesiteswereused
toclone thePCR fragment intopGEM11-zf+, yieldingplasmidpGEM11nysN1.5.
The latter plasmid was used as a template for site-directed mutagenesis
(QuickChange kit, Stratagene) to introduce nysN mutations CL346AS using
the oligonucleotides CL346AS-F: 50-TCGGCTACGGTGTCCACGCTAGCCT
GGGCCAGAAC CTGG-30 and CL346AS-R: 50-CCAGGTTCTGGCCCAGGC
TAGCGTGGACACCGTAG CCGA-30. Altered nucleotides are indicated in
bold while the new NheI restriction site introduced is underlined. Mutation
was first confirmed by restriction analysis and then verified by DNA sequenc-
ing. The mutated 1.3 kb FspAI/Bpu1102I fragment from the resulting plasmid
was cloned back into the corresponding sites of pGM11nysN4.1, yielding
pGM11nysN4.1-CL346AS. From the latter construct, the 4.1 kb insert contain-
ing mutated nysN genes was excised with EcoRI/HindIII and ligated with the
3.1 kb EcoRI/HindIII fragment of pSOK201, yielding plasmid pKOnysN-
CL346AS, which was used for nysN replacement in S. noursei.
Inactivation of NysJ KR17
The 4.0 kb PmlI/BamHI fragment from the recombinant phage N98 (Table S1)
wasexcisedand ligated into theHincII/BamHI sitesof vector pGEM3-zf+, yield-
ing plasmid pBB4.0. A 1.5 kb DNA fragment, including the KR17 active site
region, was PCR amplified from pBB4.0 using primers KR17-F: 50-TTTT
CTGCAGGCCGCGGTGCGCGC-30 and KR17-R: 50-TCCGGC ATGGTCCGTG
AAACC-30. The PCR product was digested with PstI (site underlined) and SacI
(recognition site in the amplified DNA fragment), and the 1.4 kb fragment was
ligated into the corresponding sites of pLITMUS28. The resulting plasmid,
pLIT1.4, was used as a template for site-directedmutagenesis with oligonucle-
otides KR17-mut1: 50-GCCCCGGCCAGGGCA ACTTCGAAGCCGGCAACAC
GTTCC-30 and KR17-mut2: 50-GGAACGTGTTGCCGGCTTCGAAGTTGCCCT
GGCCGGGGC-30. Altered nucleotides are indicated in bold while new
BstBI restriction site introduced is underlined. Correct mutation was verified
with BstBI digestion, and the entire insert of the mutated plasmid was verified
by DNA sequencing. From the resulting plasmid, pLIT1.4 m, the 1072 bp BclI/
AccIII fragment, was excised and used to replace the corresponding fragment
in pBB4.0, yielding plasmid pBB4.0 m. The entire 4.0 insert of pBB4.0 m
was excised with EcoRI and HindIII and ligated together with the 3.1 kb
EcoRI/HindIII fragment of pSOK201, yielding the KR17 inactivation vector
pKR17m.
Inactivation of NysJ KR16
The 14 kb XbaI insert of the recombinant phage N20 (Table S1) was ligated into
plasmid pGEM-3zf, and from the resulting plasmid, pL20X, the 3.7 kb BamHI
fragment was excised and ligated into pGEM-3zf+, yielding plasmid
pGEMB3.7. A 0.8 kb DNA fragment (encompassing the codon for the KR16
active site residue Y3404) was PCR-amplified from pGEMB3.7 with primers
KR16-F1: 50-ttttctgCAGCCGACCGGCACCGTCC-30, and KR16-1R: 50-tttt
aaGCTTCCTGGAC CGCGCGGG-30. The PCR product was digested with
PstI and HindIII (recognition sites underlined in the two PCR primers) and
ligated into the corresponding sites of pLITMUS28, yielding pLITPH0.8. The
latter plasmid served as a template for site-directed mutagenesis to introduce
the KR16 double mutation YA3404FE using the mutagenic oligonucleotides
mutKR16-1F: 50-CCCCGGCCAGGCCGGCTTCGAAGCCG CCAACGCGGTC
C-30 (sense) andmutKR16-1R: 50-GGACCGCGTTGGCGGCTTCGAAGCCGG
CCTGGCCGGGG-30 (antisense). Mutated nucleotides are shown in bold, and
the new BstBI recognition site introduced is underlined. The correct mutation
was identified by BstBI digestion and verified by DNA sequencing. From the
plasmid containing desired mutation, the 627 bp Bpu102I/Bpu10I fragment
was excised and used to replace the corresponding fragment in pGEMB3.7,
yielding plasmid pGEMB3.7 m. From the latter plasmid, the entire 3.7 kb insert
was excised with EcoRI/HindIII and ligated together with the 3.1 kb EcoRI/
HindIII fragment of pSOK201, yielding KR16 inactivation vector pKR16m.
The latter vector was introduced into the nysA-deficient S. noursei mutant
GG5073SP (Borgos et al., 2006a) by double homologous recombination.8 Elsevier Ltd All rights reserved
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The constructed gene replacement vectors (see above) were introduced to the
S. noursei strains by conjugation, and gene replacements were selected after
double homologous recombination, as described elsewhere (Sekurova et al.,
1999). The correct chromosomal mutations were verified by PCR, DNA
sequencing of PCR products, and Southern blot analyses. Polyene macrolide
production was restored in the recombinant strains by introducing the nysA
gene as described elsewhere (Brautaset et al., 2003).
Preparative LC-MS Purification of Genetically Modified Polyenes,
MS/MS, and NMR Experiments
The LC-MS-guided purification was performed essentially as described else-
where (Bruheim et al., 2004; Borgos et al., 2006b), but with methanol instead of
acetonitrile as the mobile phase organic constituent (from 70% up to 80%
methanol, depending on the polyene to be purified). Purity and concentration
of the engineered polyenes was determined by reference to USP standards of
nystatin and AmB for tetraenes and heptaenes, respectively, assuming that
molar extinction coefficients in the spectral regions of interest were unaltered.
Peak UV absorption at 309 nm and 386 nm, arising from the polyene region,
was used for tetraenes and heptaenes, respectively. Samples for MS/MS
analyses were prepared by dissolving purified compounds in DMSO to a final
concentration of 5 mg/ml. The MS/MS analysis was performed using the
Agilent 1200 series LC/Qtof system. The eluent was 30% acetonitrile in water
at a flow rate of 0.4 ml/min. An Agilent Zorbax Bonus-RP 2.13 50 mm column
was used. The Qtof mass spectrometer was operated with the electrospray
ionization source in positive ionization mode. Drying gas flow was 11 l/min,
and nebulizer pressure was 45 psi. Drying gas temperature was 350C and
the fragmentor voltage was 175 V. During MS/MS spectra acquisition, a fixed
collision energy of 25 V was used. Samples for NMR spectroscopy were
prepared by dissolving freeze-dried compounds purified by preparative
HPLC in d6-DMSO at 1 mM final concentration. To be able to perform direct
comparison of NMR assignments reported previously (Bruheim et al., 2004)
and obtained in the present study, both sample and further NMR experimental
conditions were maintained analogous to those already described. All NMR
experiments were recorded at 298 K on a Bruker DRX600 spectrometer
equipped with a 5-mm z-gradient TXI (H/C/N) cryogenic probe. Proton and
carbon chemical shifts were referenced to TMS signal. To monitor the chem-
ical structure of the investigated compounds, both one-dimensional 1H and
two-dimensional COSY and 1H-13C HSQC spectra were recorded. Detailed
description and analysis of the results are given in the Supplemental Material.
Determination of In Vitro Antifungal and Hemolytic Activity
Determination of in vitro antifungal activity was done by cultivating C. albicans
in 96-well plates and monitoring cell growth in the presence of 24 different
concentrations of antibiotics, as described elsewhere (Borgos et al., 2006b;
Nedal et al., 2007). MIC50 and MIC90 values, representing minimum inhibitory
concentrations causing 50% and 90% inhibition of cell growth, respectively,
were calculated from at least 3 parallel experiments. Hemolytic assays for
the genetically modified polyene macrolides were performed by monitoring
their ability to cause lysis of defibrinated horse blood erythrocytes washed
from plasma proteins with PBS buffer, as described elsewhere (Borgos et al.,
2006b; Nedal et al., 2007). Antibiotic solutions were prepared in DMSO to
achieve final concentrations between 0 and 200 mg/ml, and the mixtures
were incubated at 37C for 1 hr before the optical densities of supernatants
at 545 nmwere measured. The results presented are mean values from 3 inde-
pendent measurements. Hemolytic concentrations causing 50% hemolysis,
HC50 values, were determined from the generated plots (Figure S12).
In Vivo Testing of Acute Toxicity and Antifungal Activity
All animal experiments were performed in accordance with the Guidelines for
Drugs Toxicity Testing on Animals approved by the Russian Academy of Med-
ical Sciences (RAMS). Prior to initiation of experiments, the protocols were re-
viewed and approved by the Ethical Committee of the Gause Institute of New
Antibiotics (RAMS). Male mice (weight, 19–22 g) of first generation hybrids
BDF1 (S57Bl 3 DBA2) received from the Central Nursery of RAMS were
used in the experiments. The animals were kept on a standard diet consisting
of briquette forages with easy access to potable water in the animal nursery of
the Gause Institute of New Antibiotics. After the fortnight quarantine, healthyChemistry & Biology 15, 1198–12animals were divided into groups with six individuals in each and were entered
into the experiments.
Nystatin, AmB, S44HP, BSG002, BSG005, and BSG020 (5 mg) were each
mixed with dry sodium deoxycholate (4.1 mg) in a sterile glass vial. Ten millili-
ters of phosphate buffer (NaH2PO4, 1.59 g; Na2HPO4, 0.96 g; and H2O, to
100 ml) was added and immediately subjected to vigorous shaking for
10 min until homogeneous suspensions were formed. The obtained suspen-
sions were placed into the new sterile glass vials, 5% neutral sterile glucose
solution was added, and the resulting solutions (up to 0.8 mg/ml) were used
for intravenous administration.
Acute Toxicity
Freshly prepared antibiotic solutions were individually injected into the
mouse’s tail vein at <0.5 ml per minute. Each antibiotic was used in a range
of doses resulting in 0% to 100% lethality and aminimum of three intermediate
doses. Toxicity-characterizing doses MTD and LD50 were calculated with the
method of ‘‘probit’’ analysis, according to Litchfield andWilcoxon (1949), using
the statistical analysis program StatPlus (version 3.5.0., 2005).
Antifungal Activity
Mice were infected intravenously with 106 CFU of C. albicans ATCC 14053 per
mouse (0.1 ml). Thirty minutes after infection, antibiotics (six doses, ranging
from 1% to 95% MTD, three mice per dose per antibiotic) were administered
through the lateral tail vein. Each dose was administered once a day for four
days, including the day of infection (0, 1, 2, and 3 days). As a control, a group
of untreated infected mice and a placebo group of noninfected animals, which
were intravenously administered 0.2 ml of the solvent (phosphate buffer + 5%
glucose [1:1]), were used. On the fifth day of the experiment, mice were
weighed and sacrificed. The C. albicans kidney burden for each mouse was
determined by counting CFUs in homogenates from the kidneys. The kidneys
were removed aseptically, weighed, and pounded in porcelain mortars with
sterile corundum; dilutions of the resulting suspensions were prepared and
plated on Sabouraud dextrose agar. The plates were incubated for up to
72 hr at 35C, colonies of C. albicans were counted, and the load was esti-
mated per 1 g of kidney tissue. Statistical analysis was performed with Micro-
soft Office Excel 2003. Significant distinctions had a p% 0.05 at comparison
by Student T-criterion.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, two
tables, and twelve figures and can be found with this article online at http://
www.chembiol.com/cgi/content/full/15/11/1198/DC1/.
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